With the goal of accelerating research on major neuropsychiatric disorders, One Mind, in partnership with Janssen Research & Development, Otsuka Pharmaceuticals, Kaiser Permanente, the Gifford Foundation, and Bettina Bryant, is accepting applications for its Rising Star Research Awards, which recognizes and funds promising, early-career investigators.
The program seeks to fund research directed at understanding the fundamental characteristics and biological mechanisms of brain function and disfunction, as well as the translation of basic science mechanisms into better diagnostics and treatments for neuropsychiatric disorders. Of particular interest is research dedicated to schizophrenia and/or depression. Studies that use exiting data and collaborations to accelerate discovery and knowledge also are encouraged.
Examples of relevant research through this opportunity include but are not limited to studies focused on the biological mechanisms of neuropsychiatric and/or neurotraumatic disorder(s); the identification of pharmacological and non-pharmacological therapeutic targets; the development of new or refinement of existing models for studying neuropsychiatric and/or nearotraumatic disorders; the development of new or improvement of existing tools for studying brain health; the identification or advancement of biomarker development for neuropsychiatric disorder(s); the development of targeted therapies to prevent the onset or progression of neuropsychiatric disorders, mitigate their negative effects on brain function and behavior, and/or promote recovery; the characterization of similarities and differences in biological mechanisms between two or more neuropsychiatric disorders, and/or characterization of the effects of comorbid conditions on diagnosis, prognosis, and treatments; the external validation of promising biomarkers, diagnostic tools, and treatments; a comparison of the effects of treatments on whole or select patient populations; and the generation of new hypotheses from existing clinical data and their testing in relevant preclinical or computational models, or in small pilot clinical studies.
Applicants whose proposals can be enhanced with optical methods to investigate links between neural circuit/ensemble dynamics and disease phenotypes are encouraged to apply for a supplemental technology grant from Inscopix. Proposals within this category might include but are not limited to signal analysis in health vs. disease, and/or how circuit/ensemble signatures change and evolve during disease progression and in therapeutic intervention paradigms; studies that use established or new rodent models of neuropsychiatric disorders to extract key characteristics of the pathophysiology in a cell type- and/or circuit-specific manner; and investigations into the causal role of disease circuit/ensemble dynamics identified with nVoke/nVista and potentially in conjunction with other methods such as pharmacology, chemogenetics, electrophysiology, and cell ablation.
Up to five award recipients will receive $250,000 over three years. In addition, up to three supplemental technology grants will be awarded, with each including a state of the art nVoke miniature microscope system, full scientific support, and full technical support. Applicants may apply for the technology grant only as a supplement to a Rising Star Award proposal and cannot apply for the technology grant by itself.
To be eligible, candidates should be within ten years of their initial independent appointment and have demonstrated productivity and innovation in a scientific field that can be applied to the study of neuropsychiatric disorders such as attention-deficit hyperactivity disorder (ADHD), anxiety, addiction, bipolar disorder, depression, post-traumatic stress, schizophrenia, traumatic brain injury, digital therapies, or other field relevant to brain health.
See the One Mind website for complete program guidelines and application instructions.